je.st
news
Tag: merck
Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)
2014-02-03 14:30:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. GRASTEK (Timothy Grass Pollen Allergen Extract) Remains Under FDA Review in the United States WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the regulatory approval and launch of GRASTEK (Timothy grass pollen allergen extract) sublingual tablets in Canada. This represents the first approval of GRASTEK for Merck. The product is currently marketed by ALK-Abello in Europe as GRAZAX. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: approval
canadian
grass
extract
Merck joins companies ending chimpanzee research
2014-01-31 01:25:41| Biotech - Topix.net
Drugmaker Merck & Co. is joining two dozen other pharmaceutical companies and contract laboratories in committing to not use chimpanzees for research.
Tags: research
companies
ending
joins
Merck Statement on FDA Advisory Committee Meeting for RAGWITEK (Short Ragweed Pollen Allergen Extract), an Investigational Sublingual Allergy Immunotherapy Tablet
2014-01-29 03:26:07| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said it was pleased with the positive discussion of RAGWITEK (Short Ragweed Pollen Allergen Extract) at the Allergenic Products Advisory Committee meeting of the U.S. Food and Drug Administration (FDA). Language: English read more
Tags: short
statement
meeting
committee
U.S. FDA panel: data support safety, efficacy of Merck allergy drug
2014-01-28 23:10:31| Biotech - Topix.net
Merck & Co's experimental allergy drug, Ragwitek, appears safe and effective for use in patients between the ages of 18 and 65, a panel of advisors to the U.S. Food and Drug Administration concluded on Tuesday.
Tags: support
data
safety
panel
Merck Launches New Addition to the Circumvent G2 Product Line
2014-01-23 01:00:00| ThePigSite - Industry News
US - Merck Animal Health last week introduced Circumvent® PCV-M G2 - a porcine circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae combination vaccine. The new vaccine is the only one-dose or two-dose, ready-to-use combination with five-month PCV2 duration of immunity, which is 25 percent longer than any other PCV2 vaccine on the market.
Tags: line
product
addition
launches
Sites : [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] next »